Podcast

AstraZeneca Australia said it will now submit its COVID-19 vaccine to the TGA having received positive results from a late-stage trial while Moderna has finalised a supply agreement with the EU and the Russian vaccine (Sputnik V) was 91.4 per cent effective in a late-stage trial.

The entire pharmaceutical sector might be looking very closely at a proposed new law that would give the federal government significant powers to control its operation, systems and products.

The range of new innovations emerging from company pipelines mean Australia's existing systems are being "more and more tested", according to PBAC chair Professor Andrew Wilson.

More action needs to be taken to ensure Australians living with hepatitis C gain access to the direct-acting antiviral cures reimbursed via the PBS, according to the authors of a new report.

Pfizer's Anne Harris and Amgen's Shannon Sullivan have been elected to the board of Medicines Australia.

There are so many documents related to audits and investigations of NPS MedicineWise over its use of government funds for its now-defunct commercial arm the Department of Health cannot manage a freedom of information request.

Monash University has a new project that aims to use a range of new technologies to help address one of the world's most serious health issues, antimicrobial resistance.

The government signed a new funding agreement with NPS MedicineWise within weeks of receiving a report that found the organisation had improperly used a grant from the Department of Health to fund its commercial activities.

AstraZeneca has announced a late-stage trial of the COVID-19 vaccine it is developing with The University of Oxford has reported an average efficacy of 70 per cent but 90 per cent for one dosing regimen.

The year has been "one to remember in many ways" says NPS MedicineWise chair Dr Andrew Knight in the organisation's 2019-20 annual report. The organisation, which was established by the federal...

An emphatic defence of Australia's health technology assessment processes by senior Department of Health official Adriana Platona PSM at last week's BioPharmaDispatch conference.

The members of Medicines Australia "should feel very reassured" their interests are "being taken seriously and being advocated for" in the current renegotiation of its agreement with the federal government, says the association's chair Dr Anna Lavelle.